SCREENING FOR HEPATIC STEATOSIS IN TYPE 2 DIABETES MELLITUS

Abstract

The objective of this study was to analyze the high prevalence between hepatic steatosis and type 2 diabetes mellitus, the increase in morbidity and mortality due to the association of the two clinical conditions, to identify drugs that were effective and accessible for the treatment and to elucidate a diagnostic method that is also accessible and of low cost to public health. A search was carried out for pre-existing works on the SciELO and VHL platforms and a total of 28 scientific articles were included after applying inclusion and exclusion criteria. Through the studies analyzed, a high prevalence was observed between the two pathologies and the increase in morbidity and mortality due to the risks represented and added by the two clinical conditions, the cardiovascular ones being the main ones. The pharmacological class with the best therapeutic and prophylactic action in the management of the two pathologies was the sodium-glucose cotransporter-2 (iSGLT2) inhibitors. The complementary exams used for the diagnosis of NAFLD in DM2 were the laboratory tests of blood count and lipidogram associated with imaging examination by ultrasound or computed tomography of the abdomen proving some degree of hepatic steatosis, making the diagnosis cheaper and more accessible to public health. In short, it is important for health professionals to know the need for NAFLD screening in the management of type 2 diabetes mellitus, so that these patients are addressed early and correctly and have their morbidity and mortality altered.